15 results about "Hexon protein" patented technology

The invention provides a human monoclonal antibody B1AG for resisting type 4 adenovirus. The neutralizing antibody for resisting the 4-type adenovirus provided by the invention can be specifically combined with the 4-type adenovirus, and has very high affinity activity and very strong neutralizing activity at low concentration. The invention also provides application of the antibody in preparation of medicines for treating and / or preventing type 4 adenovirus diseases, and a detection kit containing the antibody.

This invention relates to the field of bioengineering technology, specifically to a recombinant adenovirus displaying a large antigen fragment on its capsid surface, its construction method, and its applications. The HVR1 and HVR5 regions of the hexon hypervariable region of this virus are replaced by gene fragments containing exogenous genes; each exogenous gene fragment has a flexible linker attached to both ends, and the gene sequence of the flexible linker is shown in SEQ ID No. 1. By precisely locating the naturally variable HVR1 and HVR5 loop regions exposed on the surface of the hexon protein as insertion sites, and supplementing them with flexible linkers, the core problem of exogenous sequence insertion disrupting the stability of the hexon structure is successfully solved. This allows for stable packaging to produce viral particles with high titers and infectivity, enabling the development of a new generation of highly efficient and safe capsid-displaying adenovirus vaccines.

The application discloses a kind of natural product antiviral drug screening method based on hexagon protein and application, belong to active ingredient screening and antiviral drug development field.The method includes: preparation nitrogen-doped mesoporous carbon and silver nanosheet composite solution, drop coating on the surface of pretreated glassy carbon electrode, after drying by activation, hexagon protein incubation, blocking and enzyme label antibody reaction, construct electrochemical sensing electrode;With the electrode, the sample to be screened natural product is incubated, and the current response signal is detected;According to signal change combination inhibition rate formula evaluation antiviral activity.The application takes hexagon protein as recognition target, based on the principle of competitive immunoassay, realizes the specific, high sensitivity detection of antiviral active ingredient in natural product, with the advantages of fast operation, low cost, small sample consumption, high throughput, etc., provides effective technical support for the mining of antiviral active ingredient in natural product such as traditional Chinese medicine.

The present invention discloses an anti-pigeon adenovirus Hexon protein monoclonal antibody, the anti-pigeon adenovirus Hexon protein monoclonal antibody is monoclonal antibody 1H5-8-14-5, wherein the amino acid sequences of the heavy chain variable region and the light chain variable region of monoclonal antibody 1H5-8-14-5 are shown in SEQ ID NO.3 and SEQ ID NO.4, respectively. The present invention also discloses a double antibody sandwich ELISA diagnostic kit for detecting pigeon adenovirus antigens, the kit comprising an enzyme labeling plate coated with an anti-Hexon protein polyclonal antibody, Hexon protein, HRP-labeled anti-pigeon adenovirus Hexon protein monoclonal antibody, a negative control, a color developing solution, a washing solution, and a stop solution. The kit of the present invention can effectively detect pigeon adenovirus, provides a new technical means for pigeon adenovirus prevention and control, and the detection result is accurate and specific, with good application value.

The present invention relates to a nanobody directed against the human adenovirus type 4 Hexon protein and its use in antiviral therapy. The nanobody has a unique CDR region, can bind to the adenovirus type 4 Hexon protein with high affinity, and can neutralize adenovirus type 4 pseudovirus with high neutralizing activity in virus neutralization assays. The present invention also provides the use of the nanobody in the preparation of a drug for treating and / or preventing diseases caused by human adenovirus type 4, as well as a diagnostic kit.

The invention discloses a human adenovirus species C having a capsid which comprises a modified adenovirus hexon protein, wherein the modified adenovirus hexon protein has a modified HVR1 region, wherein the modified HVR1 region has the sequence DEAATALEINLKKKKQAEQQ (SEQ ID NO.: 1). The invention further discloses the adenovirus of the disclosure for use in treating or preventing a human disease. The invention further discloses a nucleic acid encoding the modified adenovirus hexon protein. The invention further discloses the use of an adenovirus according to the disclosure for transducing mesenchymal stromal cells (MSCs) or tumor cells. The invention further discloses an in vitro method for transducing MSCs and a transduced MSC obtainable by the method. The invention further discloses the transduced MSC of the disclosure for use in treating a disease.

This invention discloses a recombinant lactic acid bacteria expressing a truncated avian adenovirus Hexon protein, its construction method, and its applications, belonging to the field of biomedical technology. This invention is the first to construct recombinant lactic acid bacteria strains pNZ8149-FAdV4ΔHexon / NZ3900 and pNZ8149-FAdV8bΔHexon / NZ3900 expressing the truncated avian adenovirus Hexon protein. SDS-PAGE and Western blotting analyses showed that the exogenous genes FADV4-ΔHexon and FADV-8bΔHexon were successfully expressed in *Lactococcus lactis* and exhibited reactivity. Oral immunization of one-day-old chicks showed that oral administration of the recombinant lactic acid bacteria induced humoral and cellular immunity, as well as local mucosal immunity. The results indicate that the recombinant constitutive lactic acid bacteria prepared in this invention can enhance the immunity of chicks.

This application relates to the field of biomedical technology, providing an antibody against human adenovirus hexon protein and its application. The antibody comprises a heavy chain variable region and a light chain variable region; wherein the heavy chain variable region comprises three heavy chain antigen complementary regions: amino acid sequences as shown in SEQ ID NO. 10-12; the light chain variable region comprises three light chain antigen complementary regions: LCDR1 with an amino acid sequence as shown in SEQ ID NO. 13, LCDR2 with an amino acid sequence of AAS, and LCDR3 with an amino acid sequence as shown in SEQ ID NO. 14. Related experiments have confirmed that this antibody can specifically recognize human adenovirus type 55 (HAdV) Hexon protein, with the antigenic epitope in the A180-A193 region, and can effectively prevent and control infection by HAdV-55 and / or HAdV-11 viruses.

The present invention relates to a nanobody directed against the human adenovirus type 4 Hexon protein and its use. The nanobody has a unique CDR region, can bind to the adenovirus type 4 Hexon protein with high affinity, and can neutralize adenovirus type 4 pseudovirus with high neutralizing activity in virus neutralization tests. The present invention also provides the use of the nanobody in the preparation of a drug for treating and / or preventing diseases caused by human adenovirus type 4, as well as a diagnostic kit.

The invention relates to the technical field of bioengineering, in particular to the technical field of bioengineering, and particularly relates to a recombinant adenovirus with a capsid surface displaying an oversized fragment antigen, a construction method and application. An HVR1 region and an HVR5 region of a Hexon hypervariable region of the virus are respectively replaced by gene segments containing exogenous genes; in the gene segment, the two ends of the exogenous gene are respectively connected with a flexible connection segment, and the gene sequence of the flexible connection segment is as shown in SEQ ID No.1. HVR1 and HVR5 ring regions which are accurately positioned to be exposed on the surface of Hexon protein and have natural variability are used as insertion sites, and a flexible connecting fragment is supplemented, so that the core problem that the stability of a Hexon structure is damaged by insertion of an exogenous sequence is successfully solved, and virus particles with high titer and infection activity can be stably packaged and produced; a new generation of efficient and safe capsid display type adenovirus vaccine can be developed.

The present invention relates to a nanobody directed against the human adenovirus type 4 Hexon protein and its use. The nanobody has a unique CDR region, can bind to the adenovirus type 4 Hexon protein with high affinity, and can neutralize adenovirus type 4 pseudovirus with high neutralizing activity in virus neutralization tests. The present invention also provides the use of the nanobody in the preparation of a drug for treating and / or preventing diseases caused by human adenovirus type 4, as well as a diagnostic kit.

The invention discloses a recombinant nucleic acid construct, a recombinant vaccinia virus, a vaccine composition and application thereof, and relates to the recombinant nucleic acid construct for preventing human adenovirus infection, the recombinant vaccinia virus prepared from the recombinant nucleic acid construct, the vaccine composition containing the virus, and preparation and application of the recombinant nucleic acid construct and the recombinant vaccinia virus. The technical problems that an existing multivalent vaccine is not uniform in immune effect and tedious in construction process are solved. The invention discloses a recombinant nucleic acid construct which comprises a vaccinia virus homologous recombination arm and an expression cassette unit located between the vaccinia virus homologous recombination arm. The expression cassette unit comprises human type-55, type-3 and type-7 adenovirus HEXON protein coding genes, the type-55 gene is reverse, and the type-3 and type-7 genes are forward. The recombinant vaccinia virus constructed by the method can realize stable co-expression of multivalent antigens, and is used for preparing multivalent vaccines for preventing infection of human type 3, type 7 and type 55 adenoviruses. The method is suitable for the fields of vaccine research and development, infectious disease prevention and control, viral vector technology platforms, recombinant protein or multivalent antigen expression technology and the like.

The invention relates to the technical field of animal epidemic disease detection, in particular to a monoclonal antibody aiming at canine adenovirus as well as application and a kit thereof. According to the invention, the canine adenovirus HEXON protein is used as an immune source, two hybridoma cell strains FD-CAV-2F5 and FD-CAV-4D4 are constructed, and monoclonal antibodies secreted by the hybridoma cell strains have strong specific binding capacity with canine adenoviruses (including type 1 and type 2). The monoclonal antibody is used for constructing a test strip and a kit for detecting the canine adenovirus, and the test strip and the kit have the advantages of simplicity in operation, high specificity, high sensitivity, quick result and easiness in judgment, and can be used for quickly detecting the canine adenovirus.

The invention relates to the technical field of biological medicine, and provides an anti-human adenovirus hexon protein antibody and application thereof. The antibody comprises a heavy chain variable region and a light chain variable region; wherein the heavy chain variable region comprises three heavy chain antigen complementary regions: the amino acid sequence is as shown in SEQ ID NO.10-12; the light chain variable region comprises three light chain antigen complementary regions: an LCDR1 with an amino acid sequence as shown in SEQ ID NO.13, an LCDR2 with an amino acid sequence as AAS and an LCDR3 with an amino acid sequence as shown in SEQ ID NO.14. Related experiments prove that the antibody can specifically recognize human type 55 adenovirus Hexon protein, the antigen epitope is an A180-A193 region, and infection of HAdV-55 virus and / or HAdV-11 virus can be effectively prevented and controlled.

The invention provides a human monoclonal antibody E3WS for resisting type 4 adenovirus. The neutralizing antibody for resisting the 4-type adenovirus provided by the invention can be specifically combined with the 4-type adenovirus, and has very high affinity activity and very strong neutralizing activity at low concentration. The invention also provides application of the antibody in preparation of medicines for treating and / or preventing type 4 adenovirus diseases, and a detection kit containing the antibody.